Sign in
Taking peoplePhase 2

VC005 tablets for severe alopecia areata, compared with placebo tablets

Tests VC005 tablets against placebo in adults with severe alopecia areata.

Key facts

Who runs it
Jiangsu vcare pharmaceutical technology co., LTD
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
Status
Recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
18 Aug 2026
Expected to end
30 Dec 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Drug: VC005 tablets
  • VC005 tablets
  • VC005 placebo tablets
Record updated
27 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with severe alopecia areata, a condition where hair falls out in patches. It tests VC005 tablets against a placebo (dummy tablet).

Age
18 to 65 years
Sex
All sexes
Disease stage
Severe alopecia areata. People must meet the diagnostic criteria for alopecia areata at screening and at the start of the trial.

Main reasons for not taking part

  • Pregnant or breastfeeding women, or people planning pregnancy or breastfeeding during the study
  • Current acute diffuse alopecia areata
  • Other types of hair loss that may affect the assessment, such as traction, scarring or androgenetic hair loss
  • Other scalp diseases such as scalp psoriasis, dermatitis or tinea capitis (fungal scalp infection)

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Subjects must fully understand the study, be willing and able to comply with all trial procedures, voluntarily participate in the clinical trial, and provide written informed consent by signing the informed consent form (ICF)
  • Subjects must be aged between 18 and 65 years (inclusive) at the time of ICF signing, regardless of gender
  • Subjects must meet the diagnostic criteria for alopecia areata (AA) at both screening and baseline visits

Who cannot take part

  • Subjects with a current diagnosis of other types of alopecia that may interfere with the evaluation of AA, including but not limited to traction alopecia, cicatricial alopecia, telogen effluvium, androgenetic alopecia, syphilitic alopecia, anagen effluvium, folliculotropic mycosis fungoides, or alopecia caused by thyroid disease, etc
  • Subjects with other scalp diseases that may affect the assessment of AA, such as scalp psoriasis, dermatitis, tinea capitis, etc
  • Women who are pregnant or breastfeeding, or subjects who plan to become pregnant or breastfeed during the study period
  • Subjects with a current diagnosis of acute diffuse alopecia areata (AA)

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

The 3 groups in the trial

  • VC005 Tablets Low Dose groupTreatment being tested

    Treatment: Drug: VC005 tablets

  • VC005 Tablets High Dose groupTreatment being tested

    Treatment: VC005 tablets

  • VC005 Tablets placebo groupPlacebo, for comparison

    Treatment: VC005 placebo tablets

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata
Plain-language title
VC005 tablets for severe alopecia areata, compared with placebo tabletsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT07749716, who can take part
Record updated
27 August 2026